Kindt, Nadège ; Université de Mons > Faculté de Médecine et de Pharmacie > Anatomie humaine et Oncologie expérimentale ; Université de Mons > Faculté de Médecine et de Pharmacie > Histologie
Descamps, Géraldine
Seminerio, Imelda ; Université de Mons > Faculté de Médecine et de Pharmacie > Anatomie humaine et Oncologie expérimentale
Bellier, Justine
Lechien, Jérome ; Université de Mons > Faculté de Médecine et de Pharmacie > Anatomie humaine et Oncologie expérimentale
Mat, Quentin
Pottier, Charles
Delvenne, Philippe
Journe, Fabrice ; Université de Mons > Faculté de Médecine et de Pharmacie > Service d'Anatomie humaine et Oncologie expérimentale
Saussez, Sven ; Université de Mons > Faculté de Médecine et de Pharmacie > Service d'Anatomie humaine et Oncologie expérimentale
Language :
English
Title :
High stromal Foxp3-positive T cell number combined to tumor stage improved prognosis in head and neck squamous cell carcinoma
Publication date :
08 March 2017
Journal title :
Oral Oncology
ISSN :
1368-8375
Publisher :
Elsevier, United Kingdom
Volume :
67
Pages :
183-191
Peer reviewed :
Peer Reviewed verified by ORBi
Research unit :
M112 - Anatomie humaine et Oncologie expérimentale
Research institute :
R550 - Institut des Sciences et Technologies de la Santé
[1] Stenson KM. Epidemiology and risk factors for head and neck cancer - UpToDate. UpToDate; 2016. < https://www.uptodate.com/contents/epidemiology-and-risk-factors-for-head-and-neck-cancer?> [accessed November 15, 2016].
[2] Abogunrin, S., Di Tanna, G.L., Keeping, S., Carroll, S., Iheanacho, I., Prevalence of human papillomavirus in head and neck cancers in European populations: a meta-analysis. BMC Cancer, 14, 2014, 968, 10.1186/1471-2407-14-968.
[3] Vlantis, A.C., Human papilloma virus and oropharyngeal carcinoma - lessons from history. Chin J Dent Res Off J Sci Sect Chin Stomatol Assoc CSA 19 (2016), 9–16, 10.3290/j.cjdr.a35692.
[4] Descamps, G., Karaca, Y., Lechien, J.R., Kindt, N., Decaestecker, C., Remmelink, M., et al. Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients. J Cancer Res Clin Oncol 142 (2016), 2185–2196, 10.1007/s00432-016-2203-7.
[5] Kindt, N., Descamps, G., Seminerio, I., Bellier, J., Lechien, J.R., Pottier, C., et al. Langerhans cell number is a strong and independent prognostic factor for head and neck squamous cell carcinomas. Oral Oncol 62 (2016), 1–10, 10.1016/j.oraloncology.2016.08.016.
[6] Nguyen, N., Bellile, E., Thomas, D., McHugh, J., Rozek, L., Virani, S., et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck, 2016, 10.1002/hed.24406.
[7] Pedroza-Gonzalez, A., Verhoef, C., Ijzermans, J.N.M., Peppelenbosch, M.P., Kwekkeboom, J., Verheij, J., et al. Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatol Baltim Md 57 (2013), 183–194, 10.1002/hep.26013.
[8] Sugiyama, D., Nishikawa, H., Maeda, Y., Nishioka, M., Tanemura, A., Katayama, I., et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+ CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA 110 (2013), 17945–17950, 10.1073/pnas.1316796110.
[9] Tao, H., Mimura, Y., Aoe, K., Kobayashi, S., Yamamoto, H., Matsuda, E., et al. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer Amst Neth 75 (2012), 95–101, 10.1016/j.lungcan.2011.06.002.
[10] Tang, Y., Xu, X., Guo, S., Zhang, C., Tang, Y., Tian, Y., et al. An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma. PLoS ONE, 9, 2014, e91551, 10.1371/journal.pone.0091551.
[11] Sayour, E.J., McLendon, P., McLendon, R., De Leon, G., Reynolds, R., Kresak, J., et al. Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol Immunother CII 64 (2015), 419–427, 10.1007/s00262-014-1651-7.
[12] Vlad, C., Kubelac, P., Fetica, B., Vlad, D., Irimie, A., Achimas-Cadariu, P., The prognostic value of FOXP3+ T regulatory cells in colorectal cancer. J BUON Off J Balk Union Oncol 20 (2015), 114–119.
[13] Haas, M., Dimmler, A., Hohenberger, W., Grabenbauer, G.G., Niedobitek, G., Distel, L.V., Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol, 9, 2009, 65, 10.1186/1471-230X-9-65.
[14] Badoual, C., Hans, S., Rodriguez, J., Peyrard, S., Klein, C., Agueznay, N.E.H., et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res Off J Am Assoc Cancer Res 12 (2006), 465–472, 10.1158/1078-0432.CCR-05-1886.
[15] Duray, A., Descamps, G., Decaestecker, C., Sirtaine, N., Gilles, A., Khalifé, M., et al. Human papillomavirus predicts the outcome following concomitant chemoradiotherapy in patients with head and neck squamous cell carcinomas. Oncol Rep 30 (2013), 371–376, 10.3892/or.2013.2415.
[16] Kindt, N., Preillon, J., Kaltner, H., Gabius, H.-J., Chevalier, D., Rodriguez, A., et al. Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: clinical and experimental studies. J Cancer Res Clin Oncol 139 (2013), 727–737, 10.1007/s00432-013-1375-7.
[17] Venet, F., Pachot, A., Debard, A.-L., Bohe, J., Bienvenu, J., Lepape, A., et al. Human CD4+ CD25+ regulatory T lymphocytes inhibit lipopolysaccharide-induced monocyte survival through a Fas/Fas ligand-dependent mechanism. J Immunol Baltim Md 2006:177 (1950), 6540–6547.
[18] Shang, B., Liu, Y., Jiang, S., Liu, Y., Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep, 5, 2015, 15179, 10.1038/srep15179.
[19] Salama, P., Phillips, M., Grieu, F., Morris, M., Zeps, N., Joseph, D., et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 27 (2009), 186–192, 10.1200/JCO.2008.18.7229.
[20] Bron, L., Jandus, C., Andrejevic-Blant, S., Speiser, D.E., Monnier, P., Romero, P., et al. Prognostic value of arginase-II expression and regulatory T-cell infiltration in head and neck squamous cell carcinoma. Int J Cancer 132 (2013), E85–E93, 10.1002/ijc.27728.
[21] Loddenkemper, C., Schernus, M., Noutsias, M., Stein, H., Thiel, E., Nagorsen, D., In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer. J Transl Med, 4, 2006, 52, 10.1186/1479-5876-4-52.
[22] Punt, S., van Vliet, M.E., Spaans, V.M., de Kroon, C.D., Fleuren, G.J., Gorter, A., et al. FoxP3(+) and IL-17(+) cells are correlated with improved prognosis in cervical adenocarcinoma. Cancer Immunol Immunother CII 64 (2015), 745–753, 10.1007/s00262-015-1678-4.
[23] Punt, S., Dronkers, E.A.C., Welters, M.J.P., Goedemans, R., Koljenović, S., Bloemena, E., et al. A beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17(+) cell frequency. Cancer Immunol Immunother CII 65 (2016), 393–403, 10.1007/s00262-016-1805-x.
[24] Russell, S., Angell, T., Lechner, M., Liebertz, D., Correa, A., Sinha, U., et al. Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma. Head Neck Oncol, 5, 2013, 24.
[25] Narayan, S., Choyce, A., Linedale, R., Saunders, N.A., Dahler, A., Chan, E., et al. Epithelial expression of human papillomavirus type 16 E7 protein results in peripheral CD8 T-cell suppression mediated by CD4+ CD25+ T cells. Eur J Immunol 39 (2009), 481–490, 10.1002/eji.200838527.
[26] Molling, J.W., de Gruijl, T.D., Glim, J., Moreno, M., Rozendaal, L., Meijer, C.J.L.M., et al. CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer 121 (2007), 1749–1755, 10.1002/ijc.22894.
[27] Mandal, R., Şenbabaoğlu, Y., Desrichard, A., Havel, J.J., Dalin, M.G., Riaz, N., et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight, 1, 2016, e89829, 10.1172/jci.insight.89829.
[28] De Meulenaere, A., Vermassen, T., Aspeslagh, S., Vandecasteele, K., Rottey, S., Ferdinande, L., TILs in head and neck cancer: ready for clinical implementation and why (Not)?. Head Neck Pathol, 2016, 10.1007/s12105-016-0776-8.
